secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001641172-25-023496
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic Q2 revenue up 150% to $967K; net loss narrows; completes $5.3M equity offering
--------------------------------------------------------------------------------

- Q2 2025 revenue $967K vs $386K YoY; net loss $1.794M ($0.06/share) vs $2.045M ($0.07).
- Cash $7.3M at June 30; $5.3M net from August 1 equity offering (6.052M shares at $0.95).
- Rebranded as Dyadic Applied BioSolutions; targeting 2025 commercial launch of animal-free serum albumin with Proliant.
- Received $1.5M second installment from Gates Foundation mAb grant; expects $500K Proliant milestone in Q3 2025.
- Inzymes milestone $250K received; EN3ZYME enzyme cocktail launched with Fermbox Bio under revenue share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000164117225023496/0001641172-25-023496-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000164117225023496/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023496

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer